Aethlon Medical shares are trading higher after the company received Ethics Committee approval for its Hemopurifier clinical trial in cancer patients with solid tumors unresponsive to anti-PD-1 therapy.
Portfolio Pulse from Benzinga Newsdesk
Aethlon Medical shares are trading higher after receiving Ethics Committee approval for its Hemopurifier clinical trial in cancer patients with solid tumors unresponsive to anti-PD-1 therapy.
June 18, 2024 | 12:13 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Aethlon Medical shares are trading higher after receiving Ethics Committee approval for its Hemopurifier clinical trial in cancer patients with solid tumors unresponsive to anti-PD-1 therapy.
The approval for the Hemopurifier clinical trial is a significant milestone for Aethlon Medical, potentially leading to advancements in cancer treatment and increased investor confidence. This news is likely to positively impact the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100